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Objective: Cardiac fibroblasts (CF) are crucial in left ventricular (LV) 
remodelling after myocardial infarction (MI). They predominantly express the 
α1 catalytic subunit of AMP-activated protein kinase (AMPKα1), while 
AMPKα2 is the major catalytic isoform in cardiomyocytes. AMPKα2 is 
known to protect the heart by preserving the energy charge of cardiac myo-
cytes during injury, but whether AMPKα1 interferes with maladaptive heart 
responses remains unexplored. In this study, we aim at further substantiating 
the role of this AMPK isoform in the pathogenesis of post-MI LV remodelling 
and more particularly in the regulation of fibrotic properties of CF.
Methods: AMPKα1 knockout (KO) and wild type (WT) mice were sub-
jected to permanent ligation of the left anterior descending coronary artery to 
mimic MI. Cardiac fibrosis was monitored using qRT-PCR analysis, histology 
and immunohistofluorescent staining. LV function and remodelling was 
assessed by echocardiography.
Results: In the absence of AMPKα1, the CF proliferative response was 
increased in infarcted myocardia. It resulted in elevated levels of fibrotic fac-
tors but did not lead to excessive matrix deposition or degradation in KO 
infarcts. While CF proliferation was increased, expression of the myodifferen-
tiation marker a-smooth muscle actin was decreased. This faulty maturation of 
myofibroblasts might derive from down-regulation of the transforming growth 
factor-β1/p38 mitogen-activated protein kinase pathway in KO infarcts. 
Although infarct size was similar in KO and WT hearts subjected to MI, these 
changes resulted in defective scar collagen maturation. This was associated 
with an exacerbated adverse remodelling as indicated by increased LV dia-
stolic dimension 30 days after MI.
Conclusion: Our data genetically demonstrate the centrality of AMPKα1 
in post-MI scar formation and highlight the specificity of this catalytic isoform 
in cardiac fibroblast/myofibroblast biology.
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In many pathological conditions, a sudden lack of energy, accompanied by 
an increased reactive oxygen (ROS) level and calcium overload, accelerates cell 
death with necrotic features. As the mitochondrion is the main source of cellular 
ATP and ROS, it has become an attractive therapeutic target for human 
pathology such as cardiac, neuronal and hepatic ischemia-reperfusion injury. In 
this context, we and others have shown that pharmacological modulation of 
ANT can prevent three acute pathologies in mice1 and recently, we hypothesized 
that activation of ANT might be an innovative strategy for cardioprotection. 
Here, we present the design and the implementation of enzymatic, cellular and 
subcellular assays and their optimization for the screening of modulators of 
ANT (i.e. inhibitors and/or activators). We miniaturized the ADP/ATP exchange 
measurement in cardiac interfibrillar and subsarcolemmal isolated mitochondria 
from rat heart, evaluated its robustness (Z-factor) in 96 well-microtiter plates 
and screened an in silico-generated library of ANT-potential ligands and small 
molecules, i.e. about 100 molecules. Cytotoxicity was evaluated in rat H9c2 and 
human HT29 cell lines and non-cytotoxic compounds (i.e. with LD50 >200 μM) 
were selected for further studies. To confirm potential hits activity directly on 
ANT, we purified the native protein from rat hearts in the presence of Triton X-
100, confirmed its purity by western-blot and incorporated it into small unila-
mellar vesicles (100 nm of diameter) as described.2 Validation of a novel ANT-
containing proteoliposome bioluminescent assay is currently on-going to 
develop a method to quantify the ability of molecules to modulate ADP/ATP 
exchange efficacy in dose-response and calculate EC50. If robust, this assay will 
be adapted to our high throughput screening platform. For a therapeutic perspec-
tive, identified molecules will be evaluated for their toxicity, druggability, and 
for their ability to influence the disease outcome in animal models as a prere-
quisite for future clinical studies.
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Background and objective: Exposure to high glucose (HG) stimulates 
NADPH oxidase (NOX2) dependent-ROS production in cardiomyocytes. 
NOX2 activation is not triggered by an increased glucose metabolism but 
results from a glucose transport through a sodium-glucose co-transporter 
(SGLT). The aim of this work is to identify potential therapeutic approaches 
to counteract glucotoxicity.
Methods and results: Primary cultures of adult rat cardiomyocytes were 
exposed to high glucose concentration (HG, 21mM). AMP-activated protein 
kinase (AMPK) activation by A769662 or Phenformin nearly suppressed ROS 
production under hyperglycemia. GLP-1, a new anti-diabetic drug, exerted a 
similar effect, blocking hyperglycemia-mediated ROS production. Interes-
tingly, GLP-1 treatment induced a AMPK activation, the maximal activation 
being observed at 100 nM. α2AMPK, the major isoform expressed in cardio-
myocytes (but not α1AMPK) was activated in response to GLP-1. Anti-ROS 
properties of AMPK were not related to change in glucose uptake or glyco-
lysis. Using in situ proximity ligation assay technology, we demonstrated that 
AMPK activation prevented p47phox translocation to the caveolar structure 
after high glucose concentration exposure, whatever the AMPK activators 
used. NOX2 activation by α-methyl-D-glucopyranoside, a glucose analog 
exclusively transported through SGLT, or by Angiotensin 2 was also counter-
acted by GLP-1. The crucial role of AMPK in limiting glucotoxicity was 
demonstrated by overexpressing a constitutively active form of AMPK using 
adenoviral infection. This overexpression prevented NOX2 activation in 
response to HG. Finally, in mice cardiomyocytes, GLP-1 did not exert protec-
tive action in the absence of α2AMPK.
In conclusion, GLP-1 induces α2AMPK activation and blocks HG-induced 
p47phox translocation to the plasma membrane, limiting glucotoxicity.
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